SCHEMBL256745

SCHEMBL256745

CC(C)c1cc(C(=O)c2ccccc2F)ccc1C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC25B P30305 2/20 0.51
CDC25A P30304 1/20 0.51
HSD17B10 Q99714 1/20 0.51
ALDH1A1 P00352 2/20 0.47
BCL2 P10415 2/20 0.44
MCL1 Q07820 2/20 0.44
ACE2 Q9BYF1 1/20 0.44
GABRA1 P14867 1/20 0.44
GABRB1 P18505 1/20 0.44
LMNA P02545 1/20 0.44
POLB P06746 2/20 0.43
AKR1C3 P42330 2/20 0.43
KDM4E B2RXH2 1/20 0.43
RXRA P19793 1/20 0.42
MAPK14 Q16539 1/20 0.42
GAA P10253 1/20 0.41
MEN1 O00255 1/20 0.41
MAPT P10636 1/20 0.41
KMT2A Q03164 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL256744 0.85 ALDH1A1 (0.49) HSD17B10ALDH1A1LMNAPOLBKDM4E
SCHEMBL15197129 0.84 ALDH1A1 (0.48) HSD17B10ALDH1A1BCL2MCL1GABRA1
SCHEMBL257674 0.82 ALDH1A1 (0.64) CDC25BCDC25AHSD17B10ALDH1A1LMNA
SCHEMBL8962320 0.82 CDC25B (0.77) CDC25BCDC25AHSD17B10ALDH1A1LMNA
SCHEMBL8075421 0.81 GABRA1 (0.64) HSD17B10ALDH1A1BCL2MCL1GABRA1
SCHEMBL15100954 0.80 CDC25A (0.48) CDC25BCDC25AHSD17B10ALDH1A1LMNA
SCHEMBL1356407 0.78 ACE2 (0.67) ALDH1A1ACE2GABRA1GABRB1POLB
SCHEMBL11529162 0.75 ESRRA (0.56) HSD17B10ALDH1A1LMNAAKR1C3KDM4E
SCHEMBL15197127 0.75 KAT6A (0.52) HSD17B10ALDH1A1LMNAPOLBKDM4E
SCHEMBL7118447 0.74 SRD5A2 (0.59) CDC25BCDC25AHSD17B10ALDH1A1AKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
EP-2612848-A1 CYCLIC AMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2013-07-10 EP disclosed
WO-2012029942-A1 CYCLIC AMIDE DERIVATIVE 大日本住友製薬株式会社 (JP) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE HDAC10, H1-10, H1-0 CDC25B 497/4885CDC25A 728/4885HSD17B10 146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.